Literature DB >> 12519570

Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

R P Mattick1, C Breen, J Kimber, M Davoli.   

Abstract

BACKGROUND: Methadone maintenance was the first widely used form of opioid replacement therapy developed to treat heroin dependence, and it remains the best-researched treatment for this problem. Despite the widespread use of methadone in maintenance treatment for opioid dependence in many countries, it is a controversial treatment whose effectiveness has been disputed.
OBJECTIVES: To evaluate the effects of methadone maintenance treatment (MMT) compared with treatments that did not involve opioid replacement therapy (i.e., detoxification, offer of drug-free rehabilitation, placebo medication, wait-list controls) for opioid dependence. SEARCH STRATEGY: We searched all the following databases up to 2001: Cochrane Drugs and Alcohol Review Group Register, the Cochrane Controlled Trials Register, MEDLINE, EMBASE, Current Contents, Psychlit, CORK [www. state.vt.su/adap/cork], Alcohol and Drug Council of Australia (ADCA) [www.adca.org.au], Australian Drug Foundation (ADF-VIC) [www.adf.org.au], Centre for Education and Information on Drugs and Alcohol (CEIDA) [www.ceida.net.au], Australian Bibliographic Network (ABN), and Library of Congress databases, available NIDA monographs and the College on Problems of Drug Dependence Inc. proceedings, the reference lists of all identified studies and published reviews; authors of identified RCTs were asked about other published or unpublished relevant RCTs. SELECTION CRITERIA: All randomised controlled clinical trials of methadone maintenance therapy compared with either placebo maintenance or other non-pharmacological therapy for the treatment of opioid dependence. DATA COLLECTION AND ANALYSIS: Reviewers evaluated the papers separately and independently, rating methodological quality of concealment of allocation, data were extracted independently for meta-analysis and double-entered. MAIN
RESULTS: Six studies met the criteria for inclusion in this review, all were randomised clinical trials, two were double-blind. There were a total number of 954 participants. The method of concealment of allocation was inadequate in one study, not clearly described in four studies, but adequate in a sixth study. Based on the meta-analysis, methadone appeared statistically significantly more effective than non-pharmacological approaches in retaining patient in treatment (3 RCTs, RR=3.05; 95%CI: 1.75-5.35) and in the suppression of heroin use (3 RCTs, RR=0.32; 95%CI: 0.23-0.44), but not statistically in criminal activity (3 RCTs, RR=0.39; 95%CI: 0.12-1.25). REVIEWER'S
CONCLUSIONS: Methadone is an effective maintenance therapy intervention for the treatment of heroin dependence as it retains patients in treatment and decreases heroin use better than treatments that do not utilise opioid replacement therapy. It does not show a statistically significant superior effect on criminal activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12519570     DOI: 10.1002/14651858.CD002209

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  12 in total

Review 1.  Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection.

Authors:  Linda R Gowing; Michael Farrell; Reinhard Bornemann; Lynn E Sullivan; Robert L Ali
Journal:  J Gen Intern Med       Date:  2005-12-07       Impact factor: 5.128

2.  Shelter-based managed alcohol administration to chronically homeless people addicted to alcohol.

Authors:  Tiina Podymow; Jeff Turnbull; Doug Coyle; Elizabeth Yetisir; George Wells
Journal:  CMAJ       Date:  2006-01-03       Impact factor: 8.262

3.  Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.

Authors:  Peter D Friedmann; Lan Jiang; Jeffrey A Alexander
Journal:  J Behav Health Serv Res       Date:  2009-03-19       Impact factor: 1.505

4.  Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.

Authors:  Alexander Y Walley; Sara Lodi; Yijing Li; Dana Bernson; Hermik Babakhanlou-Chase; Thomas Land; Marc R Larochelle
Journal:  Addiction       Date:  2020-02-25       Impact factor: 6.526

5.  The Edinburgh Addiction Cohort: recruitment and follow-up of a primary care based sample of injection drug users and non drug-injecting controls.

Authors:  John Macleod; Lorraine Copeland; Matthew Hickman; James McKenzie; Jo Kimber; Daniela De Angelis; James R Robertson
Journal:  BMC Public Health       Date:  2010-02-26       Impact factor: 3.295

6.  Changes in the characteristics and levels of comorbidity among new patients into methadone maintenance treatment program in British Columbia during its expansion period from 1998-2006.

Authors:  Behnam Sharif; Bohdan Nosyk; Huiying Sun; David C Marsh; Aslam Anis
Journal:  Subst Use Misuse       Date:  2013-06-10       Impact factor: 2.164

Review 7.  Pharmacotherapy for cannabis dependence: how close are we?

Authors:  Ryan Vandrey; Margaret Haney
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

8.  Persistence of low drug treatment coverage for injection drug users in large US metropolitan areas.

Authors:  Barbara Tempalski; Charles M Cleland; Enrique R Pouget; Sudip Chatterjee; Samuel R Friedman
Journal:  Subst Abuse Treat Prev Policy       Date:  2010-09-21

9.  Impact of one-year methadone maintenance treatment in heroin users in jiangsu province, china.

Authors:  Guohong Chen; Takeo Fujiwara
Journal:  Subst Abuse       Date:  2009-09-23

10.  Problem drug use the public health imperative: what some of the literature says.

Authors:  Gez Bevan
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.